Nebius: Ballooning Upside Masks Execution and Dilution Risks

What happened

Nebius Group has surged over 1,000% from early 2025 lows amid aggressive AI data center expansion, now targeting over 4 GW of contracted power that could imply $36 billion in annual recurring revenue. The company has dramatically raised capex plans to $20–25 billion, signaling the need for substantial future capital that could dilute existing shareholders. However, DeepValue's master report highlights that the stock's valuation at $214.8 already prices in flawless execution of tranche deployments and continued access to cheap financing. The next 6–9 months are critical, as Q3 2026 capacity delivery and the terms of planned debt financing will determine whether the growth narrative holds or stumbles on execution risks. With a WAIT rating and an attractive entry at $180, the evidence suggests the current risk/reward is skewed to the downside, especially given the potential for capital raises that could dampen the rally.

Implication

The one-year return is heavily dependent on on-time delivery of the Q3 2026 capacity expansion and the ability to secure non-dilutive debt financing. Any delays or service-level failures could trigger contract termination rights, undermining the prepaid fee model and forcing equity-linked capital raises. Insider selling concentration in late March–May 2026, including a large exercise-and-sale by the Chief Infrastructure Officer, raises concerns about management's confidence at current levels. Combined with material weaknesses in internal controls over financial reporting, the risk of restatements or delayed filings adds another layer of uncertainty. Investors should therefore remain on the sidelines until visible progress on capacity deployment and financing structure is confirmed, with an attractive entry point near $180 offering a margin of safety.

Thesis delta

The narrative has shifted from a pure AI-infrastructure growth story to a binary execution-and-financing story, where the market now prices in success but the path is fraught with risks. The DeepValue report downgraded the thesis to WAIT, emphasizing that the next 6–9 months of delivery proof and financing terms will determine whether the stock can justify its valuation. We are moving from a buy-on-dips stance to a cautious wait-and-see approach, as the risk of dilution and execution slip has materially increased.